Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Shock ; 32(2): 140-6, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19602943

ABSTRACT

Administration of sodium selenite in septic shock has been associated with apparently conflicting results that may be related to different dosing schedules. Bolus administration, leading to a transient pro-oxidative effect, could limit the inflammatory reaction and improve outcomes. We studied 21 anesthetized, mechanically ventilated, invasively monitored, and fluid-resuscitated sheep. Nine hours after inducing peritonitis by injection of autologous feces, the animals were randomized into three groups: (i) bolus injection (2 mg selenium as selenite, followed by 0.06 microg . kg-1 . h-1, n = 7); (ii) continuous infusion (4 microg . kg-1 . h-1 selenium, n = 7), or (iii) control (n = 7). No vasopressors or antibiotics were administered. All animals were monitored until spontaneous death. Peak plasma selenium values reached 4 to 14 micromol . L-1. Compared with the other groups, sheep given a bolus of sodium selenite had delayed hypotension with better maintained cardiac index, delayed hyperlactatemia, fewer sepsis-induced microvascular alterations, and a prolonged survival time (21.9 [bolus group] vs. 18.4 [continuous group] and 18.3 h [control group], P < 0.05). Hence, in this model of septic shock, the administration of a large bolus of sodium selenite (rather than a continuous administration) resulted in beneficial effects, probably by a transient oxidative effect.


Subject(s)
Peritonitis/drug therapy , Sodium Selenite/pharmacology , Animals , Female , Hypotension/blood , Hypotension/drug therapy , Hypotension/pathology , Oxidation-Reduction/drug effects , Peritonitis/blood , Peritonitis/pathology , Sheep , Sodium Selenite/blood , Time Factors
2.
J Crit Care ; 24(4): 590-4, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19577419

ABSTRACT

PURPOSE: The objective of this study was to develop a model to identify patients in whom drotrecogin alfa (activated) (DAA) might be administered for periods shorter than the recommended 96 hours. METHODS: We did a retrospective chart review of all 124 patients treated with a standard 96-hour infusion of DAA in a 31-bed department of intensive care. Using a stepwise approach, we identified and combined parameters that could help predict outcomes to achieve the best sensitivity associated with 100% specificity. RESULTS: Twenty-one (17%) of the 124 patients had a favorable outcome (left the intensive care unit within 5 days of DAA initiation); of these, 11 had an increase in arterial pH in the first 24 hours of treatment compared with 22 (21%) of the 103 patients with intermediate (intensive care unit stay >5 days after DAA initiation) or unfavorable (died within 5 days of DAA initiation) outcomes (P = not significant). Eight (72.7%) of these 11 patients and no other patient showed a decrease in sequential organ failure assessment score of at least 50% during the first 24 hours (P < .001). By combining these 2 variables, we could identify, with 100% specificity, 8 of the patients with a favorable outcome (38%) who made a prompt recovery. CONCLUSIONS: A simple model based on sequential organ failure assessment score and arterial pH can help identify patients with a rapid favorable course in whom a shorter duration of DAA treatment may be justified.


Subject(s)
Anti-Infective Agents/therapeutic use , Intensive Care Units , Protein C/therapeutic use , Sepsis/drug therapy , APACHE , Aged , Aged, 80 and over , Anti-Infective Agents/administration & dosage , Drug Administration Schedule , Female , Hospital Mortality , Humans , Length of Stay , Male , Middle Aged , Multiple Organ Failure/etiology , Multiple Organ Failure/mortality , Multiple Organ Failure/prevention & control , Protein C/administration & dosage , Recombinant Proteins/administration & dosage , Recombinant Proteins/therapeutic use , Retrospective Studies , Sepsis/complications , Sepsis/mortality
SELECTION OF CITATIONS
SEARCH DETAIL
...